Imaging Core The imaging capabilities at the Center for Translational Neuroimaging at Northeastern University offer unique capabilities for the visualization of nanopreparations in vivo. The center currently houses a high-resolution microSPECT/CT (NanoSPECT/CT, Bioscan, Inc.) and a 7T MR system (BioSpec, Bruker Biospin, Inc.) with a microPET to be installed in Q4 of this year. With extensive experience in onco-based imaging protocols, the imaging core enables the assessment of kinetics and dynamics of radio-labeled nanopreparations via SPECT and PET as well as nanopreparations for contrast enhanced MR studies. Multi-modal data acquisition support projects in drug development, intervention monitoring, disease diagnosis and tracking, and functional imaging. In addition to instrumentation and protocol development, the core offers a library of analysis functions for longitudinal studies of animal models of disease. Such functionality focuses on the tracking of nanopreparations via standard in vivo and ex vivo biodistribution analysis as well as novel sub-organ and sub-tumor metrics of distribution. The core hosts data and analysis results on a web-based data storage and analysis center dedicated to pre-clinical longitudinal imaging studies. Faculty and collaborating researchers have real-time access to data via the web-based repository along with remote scheduling and study-planning capabilities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA151881-03
Application #
8381588
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
3
Fiscal Year
2012
Total Cost
$141,973
Indirect Cost
Name
Northeastern University
Department
Type
DUNS #
001423631
City
Boston
State
MA
Country
United States
Zip Code
02115
Jhaveri, Aditi; Deshpande, Pranali; Pattni, Bhushan et al. (2018) Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma. J Control Release 277:89-101
Wang, Tao; Narayanaswamy, Radhika; Ren, Huilan et al. (2018) Phage-derived protein-mediated targeted chemotherapy of pancreatic cancer. J Drug Target 26:505-515
Kumar, Gaurav; Goldberg, S Nahum; Gourevitch, Svetlana et al. (2018) Targeting STAT3 to Suppress Systemic Pro-Oncogenic Effects from Hepatic Radiofrequency Ablation. Radiology 286:524-536
Upponi, Jaydev R; Jerajani, Kaushal; Nagesha, Dattatri K et al. (2018) Polymeric micelles: Theranostic co-delivery system for poorly water-soluble drugs and contrast agents. Biomaterials 170:26-36
Petrenko, Valery A; Gillespie, James W (2017) Paradigm shift in bacteriophage-mediated delivery of anticancer drugs: from targeted 'magic bullets' to self-navigated 'magic missiles'. Expert Opin Drug Deliv 14:373-384
van de Ven, Anne L; Tangutoori, Shifalika; Baldwin, Paige et al. (2017) Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation. Mol Cancer Ther 16:1279-1289
Pattni, Bhushan S; Jhaveri, Aditi; Dutta, Ivy et al. (2017) Targeting energy metabolism of cancer cells: Combined administration of NCL-240 and 2-DG. Int J Pharm 532:149-156
Gross, Amanda L; Gillespie, James W; Petrenko, Valery A (2016) Promiscuous tumor targeting phage proteins. Protein Eng Des Sel 29:93-103
Kitatani, K; Usui, T; Sriraman, S K et al. (2016) Ceramide limits phosphatidylinositol-3-kinase C2?-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid. Oncogene 35:2801-12
Ganta, Srinivas; Singh, Amit; Rawal, Yashesh et al. (2016) Formulation development of a novel targeted theranostic nanoemulsion of docetaxel to overcome multidrug resistance in ovarian cancer. Drug Deliv 23:968-80

Showing the most recent 10 out of 86 publications